Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dimethylcarbate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 12/20 | 0.63 |
| ▸ | BCHE | P06276 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylcarbate SCHEMBL4413044 | 0.87 | ACHE (0.67) | ACHEBCHELMNAMEN1KMT2A | |
| Dimethylcarbate SCHEMBL7633232 | 0.77 | ACHE (0.62) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL41903 | 0.77 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Dimethylcarbate SCHEMBL4413046 | 0.76 | ACHE (0.69) | ACHEBCHELMNAMEN1KMT2A | |
| SCHEMBL1920707 | 0.73 | ACHE (1.00) | ACHEBCHELMNATSHROPRM1 | |
| Hydrochloric Acid SCHEMBL28469713 | 0.72 | ACHE (0.95) | ACHEBCHELMNATSHROPRM1 | |
| Water SCHEMBL11727004 | 0.72 | ACHE (0.95) | ACHEBCHELMNATSHROPRM1 | |
| Hydrochloric Acid SCHEMBL30945416 | 0.72 | ACHE (0.95) | ACHEBCHELMNATSHROPRM1 | |
| Iodide SCHEMBL29488102 | 0.72 | ACHE (0.95) | ACHEBCHELMNATSHROPRM1 | |
| SCHEMBL29388689 | 0.71 | ACHE (0.78) | ACHEBCHELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4230202-A1 | BOWEL CARE USING IONTOPHORESIS | The United States Government Represented by the Department of Veterans Affairs (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3413888-B1 | BOWEL CARE USING IONTOPHORESIS | US GOV VETERANS AFFAIRS (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20190029989-A1 | BOWEL CARE USING IONTOPHORESIS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2019-01-31 | — | — | US | disclosed |
| EP-3413888-A2 | BOWEL CARE USING IONTOPHORESIS | United States Government as Represented by The Department of Veterans Affairs (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139794-A2 | BOWEL CARE USING IONTOPHORESIS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2017-08-17 | — | — | WO | disclosed |
| US-20160106694-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DROXIDOPA | LUNDBECK NA LTD. | 2016-04-21 | — | — | US | disclosed |
| EP-2363124-B1 | Pharmaceutical compositions comprising droxidopa | LUNDBECK NA LTD (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2809315-A1 | IMPROVING POSTURAL STABILITY ADMINISTERING DROXIDOPA | Lundbeck Na Ltd (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2134335-B1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | CHELSEA THERAPEUTICS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2013116325-A1 | IMPROVING POSTURAL STABILITY ADMINISTERING DROXIDOPA | CHELSEA THERAPEUTICS, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20090023705-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS OR ATTENTION DEFICIT DISORDERS | CHELSEA THERAPEUTICS, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2008137923-A2 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS, OR ATTENTION DEFICIT DISORDERS | CHELSEA THERAPEUTICS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008112773-A2 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | CHELSEA THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112562-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | CHELSEA THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227830-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | CHELSEA THERAPEUTICS, INC. | 2008-09-18 | — | — | US | disclosed |
| US-20080221170-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | CHELSEA THERAPEUTICS, INC. | 2008-09-11 | — | — | US | disclosed |
| EP-1948155-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DROXIDOPA | Chelsea Therapeutics Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080015181-A1 | Pharmaceutical Compositions Comprising Droxidopa | CHELSEA THERAPEUTICS, INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2008003028-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DROXIDOPA | CHELSEA THERAPEUTICS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20040082644-A1 | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DBA, THE DEPARTMENT OF VETERANS AFFAIRS | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015181-A1 | Pharmaceutical Compositions Comprising Droxidopa | COMT, ACHE, MAOA | ACHE 2/4885BCHE 86/4885LMNA 4315/4885 |
| US-20080227830-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | ADRA1D, QDPR, ADRA2C | ACHE 20/4885BCHE 409/4885LMNA 3641/4885 |
| US-20090023705-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS OR ATTENTION DEFICIT DISORDERS | COMT, DRD2, PNMT | ACHE 46/4885BCHE 64/4885LMNA 4023/4885 |
| US-20160106694-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DROXIDOPA | COMT, ACHE, MAOA | ACHE 2/4885BCHE 86/4885LMNA 4315/4885 |
| US-20080221170-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | HTR5A, FAAH, MTNR1B | ACHE 92/4885BCHE 2203/4885LMNA 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.